A

Pharma IR Inflated Claims Detector

3.90

Derivation Chain

Step 1 Samchundang Pharmaceutical technology transfer over-disclosure incident
→
Step 2 Bio-pharma IR disclosure credibility issues
→
Step 3 Automated cross-verification of IR disclosure figures

Problem

As seen when Samchundang Pharmaceutical announced a $380M contract inflated to $4B, bio-pharma technology licensing disclosures frequently overstate total values across upfront payments, milestones, and royalties. Individual investors and small-to-mid-sized asset managers ($7.5M–$37.5M AUM) lack the capacity to cross-verify original filings, contracts, and overseas partner IR materials, spending an average of 2–3 hours per trade decision and still frequently misjudging.

Solution

The tool auto-extracts contract amounts and terms from DART (Korean securities filing system) disclosures, cross-references them against overseas partner SEC/IR filings, and highlights discrepancies. It provides milestone-probability-weighted expected value calculations and peer benchmarks for comparable technology licensing deals.

Target: Small-to-mid-sized bio-focused asset managers ($7.5M–$37.5M AUM), individual biotech sector investors (ages 30–50)
Revenue Model: SaaS monthly flat rate of $74/month per account (individual), $292/month per account (institutional), 20% discount for Annual Subscription
Ecosystem Role: Regulation
MVP Estimate: 2_weeks

NUMR-V Scores

N Novelty
4.0/5
U Urgency
5.0/5
M Market
4.0/5
R Realizability
3.0/5
V Validation
4.0/5
NUMR-V Scoring System
N Novelty1-5How uncommon the service is in market context.
U Urgency1-5How urgently users need this problem solved now.
M Market1-5Market size and growth potential from proxy indicators.
R Realizability1-5Buildability for a small team with realistic constraints.
V Validation1-5Validation signal quality from competition and demand data.
Each dimension is scored 1-5 and weighted into grade S/A/B/C/D.
SaaS N=.15 U=.20 M=.15 R=.30 V=.20 Senior N=.25 U=.25 M=.05 R=.30 V=.15

Feasibility (68%)

Tech Complexity
29.3/40
Data Availability
18.8/25
MVP Timeline
20.0/20
API Bonus
0.0/15
Feasibility Breakdown
Tech Complexity/ 40Difficulty of core implementation stack.
Data Availability/ 25Practical availability and cost of required data.
MVP Timeline/ 20Expected time to ship a usable MVP.
API Bonus/ 15Bonus for viable public API leverage.
Total 100 points; below 50% is filtered out.

Market Validation (60/100)

Competition
8.0/20
Market Demand
3.8/20
Timing
20.0/20
Revenue Signals
10.5/15
Pick-Axe Fit
10.5/15
Solo Buildability
7.0/10
Validation Breakdown
Competition/ 20Signal quality from competitor landscape.
Market Demand/ 20Demand proxies from search and mention patterns.
Timing/ 20Fit with current shifts in tech, behavior, and regulation.
Revenue Signals/ 15Reference evidence for monetization viability.
Pick-Axe Fit/ 15How well the concept serves participants in a trend.
Solo Buildability/ 10Practicality for lean-team implementation.
Total 100 points; below 50 is filtered out.

Technical Requirements

Data Pipeline [medium] AI/ML [medium] Frontend [low]
Dashboard